Myeloid Therapeutics, Inc., a clinical stage mRNA-immunotherapy company, completed a $73 million financing led by Hatteras Investment Partners, with participation from new investors ARCH Venture Partners and Moore Strategic Ventures. Existing investors, including Newpath Partners, 8VC and Alexandria Venture Investments, also participated.
Myeloid Therapeutics has raised a $73 million Series A2 round that brings ARCH Venture Partners in as a new investor, as the biotech prepares to enter the clinic with its first in vivo mRNA program targeting myeloid cells.
Myeloid Therapeutics is looking across the Pacific to establish a new manufacturing site, and will be netting some major assistance from the local government as well.